Data Collection
Neurotoxicity, CIPN, Cancer
ONCOLOGY, DISEASE, RECURRENCE, CANCER
Self-reported sociodemographic characteristics, disease stage, time since diagnosis, chemotherapy, treatment status, and history of recurrence were collected at baseline, with additional physician verification of clinical information. Race and ethnicity data were self-reported by participants and included Asian, Hispanic, Native American, non-Hispanic Black, non-Hispanic White, and other (including Hispanic White and non-Hispanic mixed White and African American). Race and ethnicity were collected to ensure the balance of these characteristics between randomized groups. Baseline physical activity levels were assessed using the validated Modifiable Activity Questionnaire.To determine their CIPN score, participants completed the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity (FACT/GOG-Ntx) scale at baseline and 6 months. The FACT/GOG-Ntx scale provides a measure specifically for CIPN symptoms, including sensory, motor, and auditory problems.